...
首页> 外文期刊>Journal of psychoactive drugs >The Medicinal Use of Cannabis and Cannabinoids-An International Cross-Sectional Survey on Administration Forms
【24h】

The Medicinal Use of Cannabis and Cannabinoids-An International Cross-Sectional Survey on Administration Forms

机译:大麻和大麻素的药用用途-行政表格的国际横断面调查

获取原文
获取原文并翻译 | 示例

摘要

Cannabinoids, including tetrahydrocannabinol and cannabidiol, are the most important active constituents of the cannabis plant. Over recent years, cannabinoid-based medicines (CBMs) have become increasingly available to patients in many countries, both as pharmaceutical products and as herbal cannabis (marijuana). While there seems to be a demand for multiple cannabinoid-based therapeutic products, specifically for symptomatic amelioration in chronic diseases, therapeutic effects of different CBMs have only been directly compared in a few clinical studies. The survey presented here was performed by the International Association for Cannabinoid Medicines (IACM), and is meant to contribute to the understanding of cannabinoid-based medicine by asking patients who used cannabis or cannabinoids detailed questions about their experiences with different methods of intake. The survey was completed by 953 participants from 31 countries, making this the largest international survey on a wide variety of users of cannabinoid-based medicine performed so far. In general, herbal non-pharmaceutical CBMs received higher appreciation scores by participants than pharmaceutical products containing cannabinoids. However, the number of patients who reported experience with pharmaceutical products was low, limiting conclusions on preferences. Nevertheless, the reported data may be useful for further development of safe and effective medications based on cannabis and single cannabinoids.
机译:大麻素,包括四氢大麻酚和大麻二酚,是大麻植物最重要的活性成分。近年来,许多国家的患者越来越多地使用基于大麻素的药物(CBM),无论是作为药品还是作为草药大麻(大麻)。尽管似乎需要多种基于大麻素的治疗产品,特别是针对慢性疾病的症状改善,但仅在一些临床研究中直接比较了不同CBM的治疗效果。此处提供的调查是由国际大麻素协会(IACM)进行的,旨在通过向使用大麻或大麻素的患者询问有关其使用不同摄入方法的经验的详细问题,来促进对基于大麻素的医学的理解。这项调查由来自31个国家/地区的953名参与者完成,这是迄今为止针对大麻素类药物广泛使用者进行的规模最大的国际调查。一般而言,与不含大麻素的药品相比,参与者的草药非药品CBM获得更高的赞赏评分。但是,报告有药品使用经验的患者人数很少,这限制了对偏爱的结论。尽管如此,所报告的数据仍可用于进一步开发基于大麻和单一大麻素的安全有效药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号